Age: 51.0
Sex: M
Vaccine: COVID19
Symptoms: Bursitis, Erythema, Joint swelling, Limb discomfort, Skin exfoliation
Clinical narrative: he got progressively worse and more red, and more swollen; Skin infection; whole arm was tight  from the shoulder to his wrist; skin started peeling off; Pain on his deltoid; Severe swelling of the elbow; severe swelling of the bursa; This spontaneous case was reported by an other health care professional and describes the occurrence of VACCINATION SITE PAIN (Pain on his deltoid), JOINT SWELLING (Severe swelling of the elbow), BURSITIS (severe swelling of the bursa), SKIN EXFOLIATION (skin started peeling off), LIMB DISCOMFORT (whole arm was tight  from the shoulder to his wrist), ERYTHEMA (he got progressively worse and more red, and more swollen) and SKIN INFECTION (Skin infection) in a 51-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history reported.  Concomitant products included SERTRALINE HYDROCHLORIDE (ZOLOFT) for an unknown indication.    On 30-Oct-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Nov-2021, the patient experienced VACCINATION SITE PAIN (Pain on his deltoid) (seriousness criteria hospitalization and medically significant), JOINT SWELLING (Severe swelling of the elbow) (seriousness criteria hospitalization and medically significant) and BURSITIS (severe swelling of the bursa) (seriousness criteria hospitalization and medically significant). On 03-Nov-2021, the patient experienced SKIN EXFOLIATION (skin started peeling off) (seriousness criteria hospitalization and medically significant). On 04-Nov-2021, the patient experienced LIMB DISCOMFORT (whole arm was tight  from the shoulder to his wrist) (seriousness criteria hospitalization and medically significant). On an unknown date, the patient experienced ERYTHEMA (he got progressively worse and more red, and more swollen) (seriousness criteria hospitalization and medically significant) and SKIN INFECTION (Skin infection) (seriousness criterion hospitalization). The patient was treated with IBUPROFEN (ADVIL [IBUPROFEN]) for Adverse event, at an unspecified dose and frequency; IBUPROFEN for Adverse event, at an unspecified dose and frequency and CEFTRIAXONE SODIUM (ROCEPHIN) for Adverse event, at an unspecified dose and frequency. At the time of the report, VACCINATION SITE PAIN (Pain on his deltoid), JOINT SWELLING (Severe swelling of the elbow), BURSITIS (severe swelling of the bursa), SKIN EXFOLIATION (skin started peeling off), LIMB DISCOMFORT (whole arm was tight  from the shoulder to his wrist), ERYTHEMA (he got progressively worse and more red, and more swollen) and SKIN INFECTION (Skin infection) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Patient stated that on 1Nov2021, 36 hours after getting the booster he experienced side effects. On the early morning of the 3Nov2021 his skin started peeling off and he went to the emergency room where the doctor gave him antibiotics and send him home. On the morning he went to his primary doctor to drain his elbow and the doctor gave him Rocephin. On 4Nov2021 he got more antibiotics because he was getting better and last night the whole arm was tight from the shoulder to his wrist, and he was sent to the ER, where he got more antibiotics. He was being treated like he has a skin infection even though he didn't have any injury. This case concerns a 51 year-old, male patient with no relevant medical history, who experienced the serious (due to hospitalization) unexpected events of Vaccination site pain, Joint swelling, Skin infection, Erythema, bursitis, Skin exfoliation and limb discomfort. The events Vaccination site pain, Joint swelling and bursitis occurred approximately 2 days after the booster dose of mRNA-1273 vaccine, the event Skin exfoliation occurred approximately 4 days after the booster dose, the event limb discomfort occurred approximately 5 days after the booster dose of mRNA-1273 vaccine and the events erythema and Skin infection at an unknown date after the vaccination. The rechallenge was not applicable as the events were reported exclusively after the booster dose. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This case concerns a 51 year-old, male patient with no relevant medical history, who experienced the serious (due to hospitalization) unexpected events of Vaccination site pain, Joint swelling, Skin infection, Erythema, bursitis, Skin exfoliation and limb discomfort. The events Vaccination site pain, Joint swelling and bursitis occurred approximately 2 days after the booster dose of mRNA-1273 vaccine, the event Skin exfoliation occurred approximately 4 days after the booster dose, the event limb discomfort occurred approximately 5 days after the booster dose of mRNA-1273 vaccine and the events erythema and Skin infection at an unknown date after the vaccination. The rechallenge was not applicable as the events were reported exclusively after the booster dose. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.